Directorate Change

PROTEOME SCIENCES plc                             

                                 PRESS RELEASE                                 

                   For immediate release 5th September, 2006

                          PROTEOME SCIENCES APPOINTS                           

                            DR. PETER SCHULZ-KNAPPE                            

                     AS RESEARCH AND DEVELOPMENT DIRECTOR                      

The Board of Proteome Sciences plc ("Proteome Sciences" or "the Company") is
pleased to announce the appointment to the Board of the Company of Dr. Peter
Schulz-Knappe as Research and Development Director.

Awards of nil cost options under the Company's Long Term Incentive Plan were
granted to Dr. Schulz-Knappe on 1st August, 2006 when he joined the Group and
were calculated at a price of 36 pence per share as follows:

Number                              Face Value of the Share Award

319,444                             £115,000

The information required by rule 17 and Schedule 2 paragraph (g) of the AIM
Rules in relation to the appointment of Dr. Peter Schulz-Knappe is set out
below:

Name:                                                 Peter Schulz-Knappe                    
                                                                               
Age:                                                  44                                     
                                                                               
Previous Names:                                       N/A                                    
                                                                               
Directorships and Partnerships held in the            BioVisioN AG                           
last 5 years indicating those which are               BioVisioN KG                                                      
current:                                              Digilab BioVisioN GmbH                                          
                                                      PSK Vermögensverwaltende GmbH 
                                                      KBD Beteiligungs GmbH   
                                                      KBD GmbH & Co. KG            
                                                 
                                                                               
Unspent Convictions in relation to indictable                      
offences:                                             None                                                           
                                                                               
Details of any bankruptcies or                                             
individual voluntary arrangements:                    None                                                             
                                            
                                                                               
Details of any insolvency in respect                  BioVisioN AG - went into receivership  
of any Company that the Director                      on 21 Oct 2005                         
was a director of:                                               
                                                                               
                                                            
Details of any insolvency of any partnership of 
which the Director was a partner of:                  None
                                                                                                                                                                                                          
Details of any public criticisms etc:                 None                                   



Notes to editors:

Proteome Sciences plc

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity
proprietary technologies to detect differentially expressed proteins in
diseases. The protein biomarkers discovered in body fluids or tissues are
validated, developed and commercialised as diagnostic, prognostic or
therapeutic products through strategic alliances and out-licensing.

Through its unique ProteoSHOP® toolbox, Proteome Sciences provides high
sensitivity/high throughput proteomics solutions, including traditional two
dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein
sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology
and diagnostic companies, to discover and exploit protein biomarkers.
Sensitizer® chemical mass tags have been developed separately as a series of
stand-alone reagents.

For further information please visit www.proteomics.com

Enquiries:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Email: [e-mail]
James Malthouse, Finance Director
Email: [e-mail]
Tel: [phone]

Public Relations for Proteome Sciences
IKON Associates
Adrian Shaw
Tel: [phone]
Mobile: [phone]
Email: [e-mail]